<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170803035479N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-03-01</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Family-centered supportive program and chemotherapy complications</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of family-centered supportive program and routine care on chemotherapy complications among leukaemia patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/34952</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Blinding description: Blinding of patients, their family and researcher in this study is not possible and only statistician will not be aware of the allocation of patients to control or intervention group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Acute lymphoblastic leukaemia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention, performed in this study, is a family-based support program (Including family and patient education, determining the type of patient's diet, and psychological support). In order to patient and family member education, pamphlets/ information booklets and educational videos will be prepared. At the first meeting with patients and their family members before starting consolidated Chemotherapy (first stage or second stage), which will be held at the chemotherapy clinics, the training video provided for them will be displayed as well as video and pamphlet given to them. In the session oral explanations on the content of video and educational pamphlets will also be provided for families and patients, and the questions posed by them will be answered. This training session will be held for at least an hour. The number of patients and family members attending this session is based on the number of patients with acute lymphatic leukemia under chemotherapy on that day. After that according to the patient's condition a dietitian will be consulted in order to prepare a patient's diet. Prepared diet will be given to the family member after approval of doctor at the next session of chemotherapy. And guidelines on appropriate nutrition of these patients will be provided for the family. Afterwards, patients and their families will be followed up by phone. During the follow up period, the necessary supportive programs are used in accordance with the new drug or procedure and also controlling the side effects of chemotherapy in families and patients will be presented. Phone follow-up period will be continued for three months during chemotherapy for each patient and their families. Since, Consolidation chemotherapy is performed in these patients phone follow up will be done every two weeks (between two weeks and up to three months). If in the training sessions and in phone follow-up, need to psychological counseling on problems of patients after chemotherapy for patient and the family is confirmed, they will be referred to a psychiatrist at the Hematology Research Center. Intervention 2: Control group: Patients in control group, will be received the only routine intervention of chemotherapy clinics that include oral explanations of staff in the field of chemotherapy. This routine intervention is also being conducted at the intervention group.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Melika Babazadeh Zanjani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat St., Tohid Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6105 4325</telephone>
        <email>mlk.babazade@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leila Sayadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Tehran University of Medical Sciences, Nosrat St., Tohid Sq.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733171</zip>
        <telephone>+98 21 6105 4322</telephone>
        <email>l-sayadi@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria for patients:  Have age over 18 years old
Being able to understand and speak Persian and have the ability to read and write
Have awareness of time, place and person
Consent to participate in the study
Acute lymphatic leukemia have been diagnosed for them
For chemotherapy, at least, one of the family members who take care of patient at home accompanies him/her
Have been referred to chemotherapy clinic and have being under consolidation chemotherapy
Be the first or second turn of consolidation chemotherapy for these people
Family members Inclusion Criteria: Have age between 18 to 60 years old
Ability to understand Persian language and speak Persian, have ability of reading and writing
Being aware of time, place and person
being one of the first degree relatives of patient, and  providing patient care at home and willing to participate in the study
The patient obeys the relative
They are personnel of the health system</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients exclusion criteria: Have history of Chemotherapy in family members
being one of the health system personnel
Family member exclusion criteria: being one of the health system personnel</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C91.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute lymphoblastic leukaemia [ALL]</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention, performed in this study, is a family-based support program (Including family and patient education, determining the type of patient's diet, and psychological support). In order to patient and family member education, pamphlets/ information booklets and educational videos will be prepared. At the first meeting with patients and their family members before starting consolidated Chemotherapy (first stage or second stage), which will be held at the chemotherapy clinics, the training video provided for them will be displayed as well as video and pamphlet given to them. In the session oral explanations on the content of video and educational pamphlets will also be provided for families and patients, and the questions posed by them will be answered. This training session will be held for at least an hour. The number of patients and family members attending this session is based on the number of patients with acute lymphatic leukemia under chemotherapy on that day. After that according to the patient's condition a dietitian will be consulted in order to prepare a patient's diet. Prepared diet will be given to the family member after approval of doctor at the next session of chemotherapy. And guidelines on appropriate nutrition of these patients will be provided for the family. Afterwards, patients and their families will be followed up by phone. During the follow up period, the necessary supportive programs are used in accordance with the new drug or procedure and also controlling the side effects of chemotherapy in families and patients will be presented. Phone follow-up period will be continued for three months during chemotherapy for each patient and their families. Since, Consolidation chemotherapy is performed in these patients phone follow up will be done every two weeks (between two weeks and up to three months). If in the training sessions and in phone follow-up, need to psychological counseling on problems of patients after chemotherapy for patient and the family is confirmed, they will be referred to a psychiatrist at the Hematology Research Center</i_keyword>
      <i_keyword>Control group: Patients in control group, will be received the only routine intervention of chemotherapy clinics that include oral explanations of staff in the field of chemotherapy. This routine intervention is also being conducted at the intervention group.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea or vomiting before treatment. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Nausea after treatment. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Vomiting after treatment. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: the Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Constipation. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: the Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Diarrhea. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Pain. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Shortness of breath. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Signs of infection. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Bleeding or bruising. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Needles/numbness of hands and feet. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Problems with the skin and nails. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Hair loss. Timepoint: Before starting the first or second chemotherapy, and then in each chemotherapy session until 3 months - number of chemotherapy depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>A sore/sensitive mouth or throat. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>A change in appetite. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Weight gain or loss. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Sore/scratchy/dry eyes. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Feeling weakness. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Feeling unusual fatigue. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Difficulty sleeping. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Headaches. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Feeling distressed/anxious. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Feeling pessimistic/unhappy. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Change in sexual life. Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
      <prim_outcome>Irregular periods (in female patients). Timepoint: Before starting the first or second chemotherapy sessions, and then in each chemotherapy session until 3 months - number of chemotherapy sessions depend on the chemotherapy protocol. Method of measurement: The Chemotherapy Symptom Assessment Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-12-19</approval_date>
        <contact_name>Institutional research ethics committee of Nursing, Midwifery &amp; Rehabilitation school</contact_name>
        <contact_address>School of Nursing and Midwifery,Tehran University of Medical Sciences, Nosrat street. Tohid sq. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
